

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
  - TEXT CUT OFF AT TOP, BOTTOM OR SIDES
  - FADED TEXT
  - ILLEGIBLE TEXT
  - SKEWED/SLANTED IMAGES
  - COLORED PHOTOS
- 
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
  - GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(12) **EUROPEAN PATENT SPECIFICATION**

- (45) Date of publication and mention of the grant of the patent:  
14.05.1997 Bulletin 1997/20
- (51) Int. Cl.<sup>6</sup>: **A61K 31/335**
- (21) Application number: 93401978.7
- (22) Date of filing: 29.07.1993

(54) **Use of taxol for the manufacture of a medicament for the treatment of cancer**  
Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs  
Utilisation de taxole pour la fabrication d'un médicament pour le traitement du cancer

- (84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
- (30) Priority: 03.08.1992 US 923628
- (43) Date of publication of application:  
23.02.1994 Bulletin 1994/08
- (73) Proprietor: **BRISTOL-MYERS SQUIBB COMPANY**  
New York, N.Y. 10154-0037 (US)
- (72) Inventors:  
• Canetta, Renzo M.  
Madison, CT 06443 (US)  
• Rozenzweig, Marcel  
Guilford, CT 05437 (US)  
• Eisenhauer, Elizabeth  
Kingston, K76 2X1, ON (CA)
- (74) Representative: **VOSSIUS & PARTNER**  
Siebertstrasse 4  
81675 München (DE)

- (56) References cited:
- ANNALES OF ONCOLOGY, vol. 3, no. SUP-1, 11 March 1992; W.W. TEN BOKKEL HUIJINK, p. 120
  - INVESTIGATIONAL NEW DRUGS, vol. 9, 1991; EINZIG et al., pp. 59-64
  - JOURNAL OF CLINICAL ONCOLOGY, vol. 8, no. 7, 1990; R. B. WEISS et al., pp. 1263-1268
  - CANCER, vol. 65, no. 11, 1990; S.S. LEGHA et al., pp. 2478-2481
  - CANCER TREATMENT REP., vol. 71, no. 12, 1987; J.L. GREM et al., pp. 1179-1184
  - CANCER RESEARCH, vol. 47, no. 9, 1987; P.H. WIERNIK et al., pp. 2486-2493
  - JOURNAL OF CLINICAL ONCOLOGY, vol. 10, no. 7, 1992; G. SAROSY et al., pp. 1165-1170
  - CANCER TREATMENT REP., vol. 70, no. 5, 1986; M.G. KRIS et al., pp. 605-607
  - Canadian Oncology Nursing Journal, 1992, p.47-50
  - Physicians Data Query of the US National Cancer Institute, Accession No. PDQP-007307

EP 0 584 001 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

## Description

**FIELD OF THE INVENTION**

5 The present invention is directed to the use of products containing taxol for cancer therapy and more particularly is directed to improvements in the use of taxol in the treatment of cancer.

**BACKGROUND OF THE INVENTION**

10 Taxol is a naturally occurring compound which has shown great promise as an anti-cancer drug. For example, taxol has been found to be an active agent against drug-refractory ovarian cancer by McGuire et al. See "Taxol : A Unique Antineoplastic Agent With Significant Activity Against Advanced Ovarian Epithelial Neoplasms," Ann. Int. Med., 111, 273-279 (1989). All patents, scientific articles, and other documents mentioned herein are incorporated by reference as if reproduced in full below.

15 Unfortunately, taxol has extremely low solubility in water, which makes it difficult to provide a suitable dosage form. In fact, in Phase I clinical trials, severe allergic reactions were caused by the emulsifiers administered in conjunction with taxol to compensate for taxol's low water solubility ; at least one patient's death was caused by an allergic reaction induced by the emulsifiers. Dose limiting toxicities include neutropenia, peripheral neuropathy, and hypersensitivity reactions.

20 Brown et al, in "A Phase I Trial of Taxol Given By A 6-Hour Intravenous Infusion" J. of Clin. Oncol., Vol. 9, No. 7, pp. 1261-1267 (July, 1991) report on a Phase I Trial in which taxol was provided as a 6-hour IV infusion every 21 days without premedication. 31 patients received 64 assessable courses of taxol. One patient had a severe (or acute) hypersensitivity reaction, which required discontinuation of the infusion and immediate treatment to save the patient's life. Another patient experienced a hypersensitivity reaction, but it was not so severe as to require discontinuing the infusion. Myelosuppression was dose-limiting, with 2 fatalities due to sepsis. Non-hematologic toxicity was of Grade 1 and 2, except for one patient with Grade 3 mucositis and 2 patients with Grade 3 neuropathy. The neuropathy consisted of reversible painful paresthesias, requiring discontinuation of taxol in two patients. Four partial responses were seen (3 in patients with non-small-cell lung cancer, and one in a patient with adenocarcinoma of unknown primary). The maximum tolerated dose reported was 275 mg/m<sup>2</sup>, and the recommended Phase II starting dose was 225 mg/m<sup>2</sup>. The incidence of hypersensitivity reaction was reported to be schedule-dependent, with 6 to 24-hour infusions of drug having a 0% to 8% incidence of hypersensitivity reactions. It was also reported that hypersensitivity reactions persist with or without premedication despite prolongation of infusion times. Since these Phase I studies were conducted on terminally ill patients suffering from a variety of cancers, the efficacy of the taxol treatments could not be determined.

35 In a study by Kris et al., taxol formulated with Cremaphor EL in dehydrated alcohol was given as a 3-hour IV infusion every 21 days, with the administered dosage ranging from 15 to 230 mg/m<sup>2</sup> in nine escalation steps. Kris et al. concluded that "with the severity and unpredictability of the hypersensitivity reactions, further usage of taxol is not indicated with this drug formulation on this administration schedule." See Cancer Treat. Rep., Vol. 70, No. 5, May 1986.

40 Since early trials using a bolus injection or short (1-3 hour) infusions induced anaphylactic reactions or other hypersensitivity responses, further studies are carried out in which taxol was administered only after premedication with steroids (such as dexamethasone), antihistamines (such as diphenhydramine), and H<sub>2</sub>-antagonists (such as cimetidine or ranitidine), and the infusion time was extended to 24 hours in an attempt to eliminate the most serious allergic reactions. Various Phase I and Phase II study results have been published utilizing 24-hour infusions of taxol with maximum total dosages of 250 mg/m<sup>2</sup>, generally with the course being repeated every 3 weeks. Patients were pretreated with dexamethasone, diphenhydramine, and cimetidine to offset allergic reactions. See Einzig, et al., "Phase II Trial of Taxol in Patients with Metastatic Renal Cell Carcinoma," Cancer Investigation, 9(2) 133-136 (1991), and A.B. Miller et al., "Reporting Results of Cancer Treatment," Cancer, Vol 47, 207-214 (1981).

45 Koeller et al, in "A Phase I Pharmacokinetic Study of Taxol Given By a Prolonged Infusion Without Premedication," Proceedings of ASCO, Vol: 8 (March, 1989), recommends routine premedication in order to avoid the significant number of allergic reactions believed to be caused by the cremaphor (polyethoxylated castor oil) vehicle used for taxol infusions. Patients received dosages ranging from 175 mg/m<sup>2</sup> to 275 mg/m<sup>2</sup>.

50 Wiernik et al, in "Phase I Clinical and Pharmacokinetic Study of Taxol," Cancer Research, 47, 2486-2493 (May 1, 1987), also report the administration of taxol in a cremaphor vehicle by IV infusion over a 6-hour period in a Phase I study. Grade 3-4 hypersensitivity reactions incurred in 4 of 13 courses. The starting dose for the study was 15 mg/m<sup>2</sup> (one-third of the lowest toxic dose in dogs). Doses were escalated, and a minimum of 3 patients were treated at each dose level until toxicity was identified, and then 4-6 patients were treated at each subsequent level. The study concluded that neurotoxicity and leucopenia were dose-limiting, and the recommended Phase II trial dose was 250 mg/m<sup>2</sup> with premedication.

55 Other exemplary studies on taxol include : Legha et al, "Phase II Trial of Taxol in Metastatic Melanoma," Vol. 65 (June 1990) pp. 2478-2481; Rowinsky et al, "Phase I and Pharmacodynamic Study of Taxol in Refractory Acute Leuke-

mias," Cancer Research, 49, 4640-4647 (August 15, 1989); Grem et al., "Phase I Study of Taxol Administered as a Short IV Infusion Daily For 5 Days," Cancer Treatment Reports, Vol. 71 No. 12, (December, 1987); Donehower et al., "Phase I Trial of Taxol in Patients With Advanced Cancer," Cancer Treatment Reports, Vol. 71, No. 12, (December, 1987); Holmes et al., "Phase II Study of Taxol in Patients (PT) with Metastatic Breast Cancer (MBC)," Proceedings of the American Society of Clinical Oncology, Vol. 10, (March, 1991), pp. 60. See also Suffness, "Development of Antitumor Natural Products at the National Cancer Institute," Gann Monograph on Cancer Research 31 (1989) pp. 21-44 (which recommends that taxol only be given as a 24-hour infusion).

Weiss et al., in "Hypersensitivity Reactions from Taxol," Journal of Clinical Oncology, Vol. 8, No. 7 (July 1990) pp. 1263-1268, reported that it was difficult to determine a reliable overall incidence of hypersensitivity reactions, HSRs, because of the wide variations in taxol doses and schedules used, and the unknown degree of influence that changing the infusion schedule and using premedication has on HSR incidents. For example, of five patients who received taxol in a 3-hour infusion at greater than 190 mg/m<sup>2</sup> with no premedication, three had reactions, while only one out of 30 patients administered even higher doses over a 6-hour infusion with no premedication had a reaction. Therefore, this suggests that prolonging the infusion to beyond 6 hours is sufficient to reduce HSR incidents. Nevertheless, Weiss et al. found that patients receiving 250 mg/m<sup>2</sup> of taxol administered via a 24-hour infusion still had definite HSRs. Thus, while prolonging drug infusion to 6 or 24-hours may reduce the risk for an acute reaction, this conclusion can not be confirmed, since 78% of the HSR reactions occurred within ten minutes of initiating the taxol infusion, which indicates that the length of time planned for the total infusion would have no bearing. Further, concentration of taxol in the infusion may also not make a difference since substantial numbers of patients had reactions to various small taxol dosages. Finally, not only is the mechanism of taxol HSR unknown, it is also not clear whether taxol itself is inducing HSRs, or if the HSRs are due to the excipient (Cremaphor EL ; Badische Anilin und Soda Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany). Despite the uncertainty as to whether or not premedication had any influence on reducing the severity or number of HSRs, prophylactic therapy was recommended, since there is no known danger from its use.

In Annales of Oncology, Vol. 3, suppl. 1 (publ. 11.03.1992), page 12, abstr. no. 244, the use of taxol against ovarian cancer in a 3-hour-infusion is disclosed as being feasible. This document does not disclose that neutropenia is reduced simultaneously, as shown in table 2 of the present application and there are no efficacy results from less-than-3-hours experiments.

In Investigational New Drugs, Vol. 9, 1991, p. 59-64, it is shown that the administration of 250 mg/m<sup>2</sup> of taxol in combination with specific concomitantly given drugs as a 24-hours-infusion has led to three complete responses in melanoma-patients.

The document Journal of Clinical Oncology, Vol. 10, No. 7 (July 1992), p. 1165-70 is a study on the effects of an administration of taxol in particular with G-CSF support in refractory ovarian cancer.

The document Cancer, Vol. 65, 1990, p. 2478-2481 is a study of the use of taxol at doses of 250 mg/m<sup>2</sup> in continued infusions of 24 hours. A premedication with dexamethasone and diphenhydramine hydrochloride has been done.

The document Cancer Treatment Reports, Vol. 70, No. 5 (1986), p. 605-607 shows that a 3-hour infusion at doses of 15 up to 230 mg/m<sup>2</sup> does not show anti-tumor activity but rather gave rise to hypersensitivity reactions.

In an article published by nurses in Canadian Oncology Nursing Journal, 1992, p. 47-50, they report about a study to determine the optimal dose and duration of taxol treatment of women with ovarian cancer. There is no indication that the 3-hours or less infusions cause less haematological toxicity, in particular reducing neutropenia, as shown in table 2 of the present application.

The conflicting recommendations in the prior art concerning whether premedication should be used to avoid hypersensitivity reactions when using prolonged infusion durations, and the lack of efficacy data for infusions done over a six hour period has led to the use of a 24-hour infusion of high doses (above 170 mg/m<sup>2</sup>) of taxol in a Cremaphor EL emulsion as an accepted cancer treatment protocol.

Although it appears possible to minimize the side effects of administering taxol in an emulsion by use of a long infusion duration, the long infusion duration is inconvenient for patients, and is expensive due to the need to monitor the patients for the entire 6 to 24-hour infusion duration. Further, the long infusion duration requires that patients spend at least one night in a hospital or treatment clinic.

Thus, it is highly desirable to develop a taxol infusion protocol which would allow for recipients to be treated on an out-patient basis. Since taxol infusions are generally preceded by premedication, and require post-infusion monitoring and record keeping, it is highly desirable that the infusion duration not exceed 6 hours, yet the infusion dosage should provide the patient sufficient taxol to have an antineoplastic effect, while not exceeding dose-limiting toxicities. It is also desirable to minimize premedication since this increases patient discomfort and increases the expense and duration of treatment.

Even if infusion duration can not be shortened, it is also desirable to avoid the high dosages of taxol presently believed necessary to have an antineoplastic effect, which induce a variety of adverse side-effects, including respiratory distress, cardiovascular irregularities, flu-like symptoms, gastrointestinal distress, hematologic complications, genitourinary effects, neuropathy, alopecia, and skin rashes.

Further, due to the extremely limited supply of taxol, and the high dosage requirement for each patient, the demand

for taxol greatly exceeds the supply.

Therefore, it is highly desirable to reduce taxol dosages, if possible, to both extend the supply of taxol and reduce the toxic side effects of taxol. It is also highly desirable to decrease the time required to administer taxol to patients to minimize patient discomfort and expense.

Thus, there is a need for products containing taxol for administration of less taxol and/or which require less infusion time.

Therefore, it is a primary object of the present invention to provide new products containing taxol which allow to administer taxol over a shorter period of time than the present 6 to 24-hour infusion protocols, while minimizing toxic effects induced by the administration of taxol.

It is another object of the present invention to provide new products containing taxol for administration of taxol which reduce the amount of taxol administered to a patient, without sacrificing the antineoplastic effects desired by administering taxol.

It is yet a further object of the present invention to provide new products containing taxol for administration of taxol which utilizes both lower dosages of taxol and shorter infusion periods, without sacrificing the antineoplastic benefits of the administration of taxol.

#### **SUMMARY OF THE INVENTION**

These and other objects of the present invention are accomplished by using products containing an anti-neoplastically effective amount of taxol and sufficient medications to prevent severe anaphylactic-like reactions formulated and packaged for separate or sequential or simultaneous administration in cancer therapy with a patient over a period of about 3 hours or less.

It is another characteristic of the invention that the anti-neoplastically effective amount of taxol is in the range from 135 mg/m<sup>2</sup> to 175 mg/m<sup>2</sup>.

The products containing an effective amount of taxol of about 135 mg/m<sup>2</sup> are particularly adapted for separate or sequential or simultaneous use in solid tumors or leukemias therapy.

It is a particularity of the invention that said medications include at least one compound selected from the group consisting of steroids, antihistamines, and H<sub>2</sub> receptor antagonists.

It is another particularity of the invention that when the anti-neoplastically efficient amount of taxol is in the range from 135 mg/m<sup>2</sup> and 175 mg/m<sup>2</sup>, said medications are selected from the group consisting of ranitidine, dexamethasone, diphenhydramine, famotidine, hydrocortisone, clemastine, cimetidine, prednisone, chlorpheniramine, chlorphenamine, dimethindene maleate, and promethazine.

It is further another particularity of the invention that the products of the invention further contain an effective amount of a colony stimulating factor.

The products containing between 135 mg/m<sup>2</sup> and 175 mg/m<sup>2</sup> of taxol are particularly adapted for separate or sequential or simultaneous use in ovarian cancer therapy.

When the products of the invention are used in the ovarian cancer therapy, said medications contain at least one compound selected from the group consisting of steroids, antihistamines, and H<sub>2</sub> receptor antagonists in an amount sufficient to reduce allergic reactions.

In case of ovarian cancer therapy, said products furthermore comprise an effective amount of a colony stimulating factor sufficient to at least reduce myelotoxicity.

In a preferred embodiment, the products of the invention are used as follows : taxol infusions are provided over a duration of about three hours, utilizing dosages of between 135 mg/m<sup>2</sup> and 175 mg/m<sup>2</sup>, after patients are pretreated to alleviate or minimize hypersensitivity responses. In a preferred embodiment, antineoplastic effects are achieved in patients suffering from cancer through administration of about 135 mg/m<sup>2</sup> administered via a 3-hour infusion following premedication to reduce or eliminate hypersensitivity responses. These results are surprising in view of the conventional understanding that a bolus injection or short (1-3 hour infusions) will induce anaphylactic reactions or other hypersensitivity responses, and that only premedication coupled with extension of the infusion time to 6-24 hours would reduce or eliminate the most serious allergic reactions.

Preferably, patients are premedicated with steroids, antihistamines, and H<sub>2</sub>-antagonists sufficient to at least prevent an anaphylactoid shock capable of causing patient death in greater than 95% of cancer patients treated, and avoid acute hypersensitivity reactions in greater than 90% of cancer patients treated.

To ameliorate myelosuppression associated with taxol administration, particularly associated with high dosages of taxol, granulocyte-colony stimulating factor (G-CSF) is given as a daily subcutaneous injection started 24-hours after the completion of a taxol infusion. With the use of G-CSF, taxol dosages of up to about 175 mg/m<sup>2</sup> can be safely administered using the products and method of the present invention.

Other aspects of the present invention include the use of the new products containing taxol for administration to a patient suffering from cancer in the frame of a treatment in which certain clinical parameters are monitoring, and in which taxol administration is temporarily halting when infusion related toxicities exceed safe limits. After the parame-

ters return to near baseline, therapy is restarted, preferably with 72 hours. In a preferred embodiment, premedication is given intravenously prior to restarting the infusion. For patients suffering severe HSRs near the end of, or after, a taxol infusion, the HSR is treated, and the patient is rechallenged during the next course by providing premedication intravenously.

Additional aspects include the administration of multiple courses of taxol over regular periods of time, such as at approximately 21-day intervals, or when adverse effects of a previous course or infusion substantially subside.

#### DETAILED DESCRIPTION OF THE INVENTION

The products of the invention will be herein described by way of their examples of method of utilization.

Despite the conventional understanding that it is necessary to infuse patients over a 24-hour period with high dosages of taxol (greater than 170 mg/m<sup>2</sup>) following premedication to minimize or eliminate hypersensitivity responses, while obtaining the desired antineoplastic effect, it has been surprisingly discovered that the new products containing taxol can be safely administered to cancer patients via infusions lasting 3 hours or less at dosages of 135 mg/m<sup>2</sup> to 175 mg/m<sup>2</sup>. In a preferred embodiment, taxol is administered via an infusion having a duration of about three hours, with a taxol dosage of about 135 mg/m<sup>2</sup> or about 175 mg/m<sup>2</sup>. Of great significance is a surprising discovery that the short term infusion causes less myelosuppression, which leads to a lower incidence of infections and fever episodes (e.g., febrile neutropenia). Following the preferred infusion schedules of the present invention provides an objective response rate of greater than 10% for patients suffering from epithelial ovarian carcinoma, and preferably an objective response rate of 14% or greater for groups of at least 150 patients suffering from ovarian carcinoma.

The surprising discovery that taxol could be safely administered via a short infusion (e.g., over about 3 hours) means that it will now be possible to administer taxol on an out-patient basis, saving patients the time and expense of yet another hospitalization while improving patient quality of life.

It has also been surprisingly discovered that lower taxol dosages, such as about 135 mg/m<sup>2</sup> can be administered via infusions having about 3-hours, and still be anti-neoplastically effective.

#### EXPERIMENTAL PROTOCOL

A multi-center, randomized comparative study of taxol in patients suffering from ovarian carcinoma which had been pretreated with platinum was carried out. The high degree of success, greater than 10% objective response, to treatment by patients suffering from drug refractory ovarian carcinoma is truly astonishing, since responses to drug refractory ovarian carcinoma are extremely uncommon. While experimental data is provided herein for the successful treatment of ovarian carcinoma with taxol using the present products and treatment protocol, it is to be understood that the products and treatment protocol can be used for the treatment of other forms of cancer with taxol, such as melanoma, renal cell carcinoma, and other cancers which are treatable with taxol. The present invention provides an improvement in the treatment of all types of cancer which can be treated with taxol, since by use of the products and administration protocol of the present invention, lower toxicities and/or less time is required than that associated with prior art products and protocols for administering anti-neoplastically effective amounts of taxol.

Patients with platinum pretreated recurrent ovarian cancer were randomized to a 135 or 175 mg/m<sup>2</sup> dose arm, administered as a 3-hour or 24-hour IV infusion, which was repeated every three weeks. Responses were evaluated every two cycles. All four treatment groups were matched for age, performance status, previous treatments, and time from last platinum therapy. If a patient showed a complete response, CR, taxol infusions were continued for four cycles post CR; patients showing a partial response, PR, had taxol infusions continued until relapse, or treatment was stopped after four cycles post PR stabilization. For a stable disease, taxol infusions were stopped after a maximum of 10 cycles or earlier if unacceptable toxicity was present; if disease progressed, PD, patients were taken off the study.

The study included four arms as indicated below:

Arms	Infusion Duration	Dosage
A	24 hours	175 mg/m <sup>2</sup>
B	3 hours	175 mg/m <sup>2</sup>
C	24 hours	135 mg/m <sup>2</sup>
D	3 hours	135mg/m <sup>2</sup>

Patients with ovarian carcinoma included in the study had been treated with and were unresponsive to a minimum

of one but no more than two platinum-containing chemotherapy regimens, and were required to have shown progression during or relapse after their last regimen of chemotherapy. Patients were treated every 21 days if allowed by toxicity. Granulocyte count and platelet count were monitored ; provided granulocyte count was at least 1500 cells/cmm and platelet count was at least 100,000 cells/cmm, taxol was administered.

#### ADMINISTRATION OF THE NEW PRODUCTS CONTAINING TAXOL

Prior to initiating an infusion, a resuscitation/emergency cart was placed outside the infusion room and remained there during the first hour of infusion. An emergency drug tray having all the necessary drugs, etc... was set up in the room in the event of an acute hypersensitivity reaction. Oxygen and suction equipment are provided at the bedside of each patient along with a 3-hour or 24-hour observation sheet (depending on the arm), and a fluid balance sheet.

Nitroglycerin tubing is required for the IV equipment because the Cremaphor EL (polyethoxylated castor oil) leaches plasticizer from regular IV tubing made of polyvinylchloride. Glass or polyolefin containers were used for storing all cremaphor containing solutions. All taxol-containing solutions were infused with in-line filtration using a microporous filter, preferably having a pore size not greater than 0.22 microns.

In order to minimize acute hypersensitivity reactions, patients were premedicated according to the protocol with dexamethasone or an equivalent (20 mg taken os at home, 12 hours and 6 hours prior to taxol infusion). Diphenhydramine (or equivalent antihistamine), 50 mg IV; and ranitidine (or equivalent H-2 receptor blocker), 50 mg IV, were provided 30 minutes prior to the taxol infusion.

Taxol was supplied by BRISTOL-MYERS SQUIBB as a concentrated sterile solution for IV administration. Each 5 ml vial contained 6 mg/ml taxol in polyethoxylated castor oil (Cremaphor EL) 50% in dehydrated alcohol, USP 50%. While an emulsion of taxol in polyethoxylated castor oil in dehydrated alcohol is utilized as a vehicle in a preferred embodiment, it is contemplated that other pharmaceutically acceptable vehicles for taxol may be used.

Taxol was administered, after dilution in dextrose or saline solution, as a continuous infusion in two 500 mL glass bottle of 5% dextrose (D5W) or normal saline (NS) over 3 hours. The first 18 mL of IV solution were infused at a fast rate (300 mL/hour) via the previously primed line to ensure that the taxol had reached the end of the IV tubing. This procedure enables the accurate assessment of the patient receiving the taxol.

A nurse remained with each patient for the first hour of each infusion. Temperature, pulse, blood pressure, and respiration were taken preinfusion, every 15 minutes for the first hour and, every thirty minutes for the next 2 hours. Other observations were also documented, such as rash/redness of the skin, hives, vomiting, nausea, and any other symptoms including neuropathy and skin rashes.

Another aspect of the present invention is that patients suffering from hypersensitivity reactions to taxol infusions can be retreated with taxol following management of the hypersensitivity reaction. In a preferred embodiment, patients experiencing hypersensitivity reactions were taken off taxol. Hypersensitivity reactions were treated by administration of diphenhydramine (50 mg IV) with administration of epinephrine 0.35-0.5 cc s.c. every 15-20 minutes until reaction subsided or until a total of six dosages of epinephrine were given. IV fluids were administered when hypotension did not respond to epinephrine. Likewise, if wheezing did not stop in response to epinephrine, 0.35 cc of nebulized albuterol solution was administered.

To prevent recurrent or ongoing allergy manifestation, 125 mg methylprednisolone was administered via IV.

In a preferred embodiment for rechallenging with taxol patients who had experienced a hypersensitivity reaction (other than hypotension requiring pressor therapy, angioedema respiratory distress requiring bronchodilation therapy, and generalized urticaria), the following protocol was followed. All rechallenge patients received a prolonged 24-hour infusion, even if the hypersensitivity reaction occurred during a 3-hour infusion. Dosage reductions in subsequent treatment courses were mandated for all patients having (1) a granulocyte count of less than 500 cells/cmm, (2) a platelet count of less than 50,000 cells/cmm for seven days or more, (3) febrile neutropenia, (4) infection, (5) hemorrhage, (6) mucositis with vesiculation and/or ulcers, or (7) vomiting appearing despite anti-emetic premedication. Taxol treatment was discontinued in patients having (1) intolerable paresthesias and/or marked motor loss (neurological toxicity of World Health Organization, WHO, grade greater than 2); (2) symptomatic bradycardia or heart block of any degree or other arrhythmias ; and (3) other major organ toxicity of WHO grade greater than 2.

If less than 75% of a total taxol dose was infused prior to a hypersensitivity reaction, retreatment preferably occurs within 72 hours of cessation of taxol infusion, and the amount of taxol used for retreatment equals to the originally planned taxol dose less the amount infused before the taxol infusion was stopped due to the hypersensitivity reaction. A non-limiting embodiment of a preferred rechallenge procedure for a 24-hour infusion follows :

A. A steroid is given. For example, 8 mg dexamethasone is given intravenously 24, 18, 12 and 6 hours prior to taxol administration.

B. An antihistamine is given 30 minutes prior to taxol, for example, 50 mg IV diphenhydramine.

C. An H2 receptor antagonist is given 30 minutes prior to taxol infusion, for example, ranitidine 50 mg IV.

D. Taxol is administered in the 24-hour infusion volume, but at one quarter the planned rate for a 24-hour IV infusion during the first 6 hours. If no reaction is noted, the rate is increased to normal infusion speed. Thus, the entire infusion time is somewhat longer than 24 hours because of the slow infusion during the first 6 hours. Thus, by way of non-limiting example, total infusion time would be approximately 28.5 hours. Taxol administration for the claimed 3 hours or less infusion time is accordingly shorter.

E. If a hypersensitivity reaction sufficient to discontinue the taxol infusion recurs during the rechallenge procedure, the patient is taken off taxol. However, if a patient is successfully rechallenged without recurrence of a hypersensitivity reaction severe enough to require discontinuation of the infusion, the rechallenge procedure is continued.

#### EFFICACY AND SAFETY

In order to confirm the efficacy and safety of the taxol administration according to the invention, patients with histologically confirmed ovarian carcinoma, who had shown progression during or relapse after platinum-containing therapy, were administered taxol according to one of the four previously described Arms. Patients ranged between 18 and 75 years in age with an Eastern Cooperative Oncology Group, ECOG, performance status of 0, 1, or 2, and had to have recovered from all toxicities of previous treatment. Further, no prior chemotherapy or radiotherapy were allowed within four weeks prior to entry into the study (patients were also not entered into the study if there had been less than six weeks since prior mitomycin, nitrosureas, or high-dose carboplatin therapy). An adequate baseline bone marrow function was required, which was defined as a granulocyte count  $\geq 2,000$  cells/cmm and a platelet count  $\geq 100,000$  cells/cmm. Adequate hepatic and renal functions were required with normal hepatic function defined as total bilirubin  $\leq 1.5$  times upper normal value and normal renal function defined as serum creatinine  $\leq 1.5$  times upper normal value. Patients with abdominal adenocarcinoma, a previous history of atrial or ventricular arrhythmias, congestive heart failure, myocardial infarction within six months preceding randomization, complete bowel obstruction, a pre-existing neuropathy  $>$  WHO grade 2, active infection, prior allergic reaction to drugs containing Cremaphor, or other serious medical condition were excluded from the study.

Eligible patients were randomized according to a computerized randomization log. During therapy, hematology data (hemoglobin, white blood cell count, granulocytes and platelets) were collected, and toxicity assessments were continuously made. After each cycle, a physical history update was recorded, as well as tumor measurement, performance status (ECOG), hematology, chemistry (serum creatinine, bilirubin, alkaline phosphatase, SGOT (AST), CA125) and a toxicity assessment. A quality of life assessment was also made after each cycle, and every two months until six months after treatment stopped.

The efficacy and safety of the improved products for administration of taxol of the present invention was based on 159 patients randomized into the four treatment Arms previously described. Of the 159 patients, 157 patients received at least one dose of taxol and were evaluated for both safety and efficacy.

528 courses of taxol were given to 157 patients distributed over the 4 treatment Arms. The median number of courses received was 3 (range 1-8), which is equivalent to a median of 9 weeks on study. Overall 27 of 157 (17%) patients required a dose reduction, mainly for neutropenia with less than 500 cells/cmm for more than 7 days duration. Taxol administration was discontinued for 2 patients during the second course. One of the 27 patients was retreated at a reduced dose level, and dosage was re-escalated after one course at a reduced dose level. Overall, 11% of the taxol courses were administered at reduced dosage.

Dose reduction was required in the 2 Arms using long term infusion more frequently than in Arms using the short term infusion. This is surprising considering that a more concentrated dosage of taxol is given during the short infusion than during the long infusion.

The time between courses ranged from 17 to 49 days, with the median number of days between courses being 21. The following table lists the various premedications used in the various treatment Arms



TABLE 1

EXAMPLES OF PREMEDICATION USED		
H-2 Receptor Blocker:	Steroid :	Antihistamine :
Ranitidine	Dexamethasone	Dyphenhydramine
Famotidine	Hydrocortisone	Clemastine
Cimetidine	Prednisone	Chlorpheniramine
		Chlorphenamine
		Dimethindene
		Maleate
		Promethazine

In a preferred embodiment, at least one of each of the H-2 receptor blockers, steroids and antihistamines is utilized. By way of non-limiting examples, a combination of prednisone and hydrocortisone, or dexamethasone and hydrocortisone could be used in combination with at least one of the antihistamines and at least one of the H-2 receptor blockers.

22 patients achieved an objective response (CR or PR). Thus, the overall objective response rate is 14% (22/157) for this study. However, 17 patients were not evaluated and another five patients were unevaluable. If these latter patients are excluded, the objective response rate is 16% (22/135). Further 51 patients with stable disease are continued on taxol and may later meet the criteria for an objective response (Note that an average of only three courses of taxol yielded the present results). Thus, use of the present products for administration of taxol produces at least a 14% overall objective response rate for 157 patients. This is an astonishing result, since all the patients were considered drug refractory. It is also remarkable that 3 out of 46 (7%) of these patients who had progressed on previous platinum containing chemotherapy responded to taxol. Overall, responses to taxol occurred in 13% of patients (14/114) who were considered resistant to platinum therapy (i.e., progression on therapy or relapse within six months). Further, 52% of patients (24/46) with disease truly refractory to platinum, and 53% of patients (16/36) with an early relapse after platinum, achieved a stabilization of their disease.

15% of the platinum resistant patients who had received one previous regimen of platinum responded to taxol versus 10% of the platinum resistant patients who had received two previous regimens of platinum, corresponding to 19 and 23%, respectively.

Of 159 patients, only one died of taxol related toxicity (less than 1%).

#### HEMATOLOGIC TOXICITY

Another aspect of the present invention is the reduction in hematologic toxicity associated with the treatment of cancer with taxol. The 157 patients who received taxol had blood counts performed weekly. White blood cell (WBC) counts, absolute neutrophil count (ANC), platelet counts, and hemoglobin (Hb) concentration were the primary variables used to evaluate products and treatment related myelosuppression. The World Health Organization, WHO, grades of nadir for the entire study population of 157 patients during course 1 are presented in the table below. Leukopenia and neutropenia were the most frequent and severe hematologic adverse effects observed during the first course of treatment. 53% (83/156) of the patients had Grade III or IV neutropenia, while 39% (61/157) had Grade III or IV leukopenia. Severe thrombocytopenia was observed in only two patients (1%) during course 1.

Of particular significance is that Grade IV neutropenia was reported almost five times more frequently in the patients treated with the 24-hour taxol infusion than the patients treated with a 3-hour taxol infusion.

TABLE 2  
Myelotoxicity Course 1 WHO Grade Per Treatment Arm

	175/24 (n=45)		175/3 (n=29)		135/24 (n=44)		135/3 (n=39)		TOTAL (n=157)	
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
<b>WBC Count</b>										
0	1	(2)	11	(38)	4	(9)	15	(38)	31	(20)
I	5	(11)	6	(21)	5	(11)	13	(33)	29	(18)
II	11	(25)	7	(24)	11	(25)	7	(18)	36	(23)
III	22	(49)	5	(17)	20	(46)	3	(8)	50	(32)
IV	6	(13)	0	-	4	(9)	1	(3)	11	(7)
<b>ANC Count</b>										
0	2	(5)	11	(38)	6	(14)	18	(46)	37	(24)
I	1	(2)	2	(7)	2	(5)	8	(21)	13	(8)
II	5	(11)	3	(10)	7	(16)	8	(21)	23	(15)
III	8	(18)	6	(21)	6	(14)	4	(10)	24	(15)
IV	28	(63)	7	(24)	23	(52)	1	(3)	59	(38)
<b>Platelet Count</b>										
0	39	(87)	29	(100)	43	(98)	36	(92)	147	(94)
I	3	(7)	0	0	1	(2)	2	(5)	6	(4)
II	1	(2)	0	0	0	0	1	(3)	2	(1)
III	1	(2)	0	0	0	0	0	0	1	(1)
IV	1	(2)	0	0	0	0	0	0	1	(1)

As is clear from Table 2, grade 4 neutropenia was reported almost 5 times more frequently in patients treated with the 24-hour taxol infusion compared to patients treated by a 3-hour infusion. 58% (51/88) of the patients treated with the 24-hour taxol infusion had grade 4 neutropenia in comparison to 12% (8/68) of the patients treated by a 3-hour infusion. When the incidence of grade 3 and grade 4 are pooled, it is clear that severe leukopenia occurs more frequently in patients treated with a 24-hour taxol infusion than with a 3-hour infusion.

With reference to Table 3 below, analysis of median values for nadir count confirms the severity of taxol induced neutropenia, especially in the two 24-hour treatment Arms.

TABLE 3

Myelotoxicity Course 1 = Nadir Counts, Per Treatment Arm

	175/24 (n=45)	175/3 (n=29)	135/24 (n=44)	135/3 (n=39)	TOTAL (n=157)
WBC Count (1)					
- median	1,600	3,300	1,900	3,700	2,400
- range	300-7,300	1,400-13,900	500-7,800	980-6,850	300-13,900
ANC Count					
- median	330	1,390	470	1,930	840
- range	0-664	210-11,770	0-555	360-6,290	0-11,770
Platelet Count					
- median	168,000	285,000	236,500	298,000	226,000
- range	11,000 -345,000	144,000 -688,000	87,000 -710,000	65,000 -749,000	11,000 -749,000

(1) Cell counts expressed in number of cells/cmm.

Further, anemia of any grade occurred in 47% (26/55) of patients with normal baseline Hb values who had been treated with a taxol long-term infusion, and anemia occurred in only 28% of patients treated with the short-term infusion. In summary, neutropenia and leukopenia were the most frequent and severe hematologic adverse effects during the

study period, with 63% of the patients displaying severe neutropenia (WHO Grade III and IV) during at least one course. The incidence of severe neutropenia in the long-term infusion versus the short-term infusion Arms was 85% versus 32%. The incidents of severe neutropenia in the high dose Arms was 74% (55/74) versus 52% (43/83) in the low dose Arms. Thus, it is clear that both reducing the dosage and the infusion time will lower hematologic toxicity ; however, reducing the infusion to 3 hours from 24 hours appears to have a greater impact on reducing toxicity than reducing the taxol dosage from about 175 mg/m<sup>2</sup> to 135 mg/m<sup>2</sup>.

Those patients suffering from myelotoxicity can be treated with colony stimulating factors, CSFs. In a preferred embodiment, patients are given granulocyte colony stimulating factors in an amount sufficient to be effective in either reducing myelotoxicity or increasing the rate of recovery from myelotoxicity. Preferably, the CSFs are provided in accordance with the above-mentioned method taught by Sarosy et al. in "Phase I Study of Taxol and Granulocyte Colony-Stimulating Factor In Patients With Refractory Ovarian Cancer," *Journal of Clinical Oncology*, Vol. 10, No. 7, (July, 1992) pp. 1165-1170. In a preferred embodiment, G-CSF (available from Amgen, Inc. of Thousand Oaks, CA) can be self-administered subcutaneously on a daily basis (thus allowing for treatment on an outpatient basis), with injections beginning 24 hours after the completion of a taxol infusion. Preferably a G-CSF dose of about 10 µg/kg/d is used, and G-CSF injection continues until there is convincing evidence of bone marrow recovery from taxol-induced nadir. Convincing evidence of bone marrow recovery includes a white blood cell count of 10,000 cells/mm<sup>3</sup> and a platelet count of more than 50,000/mm<sup>3</sup>. The use of G-CSF enables higher doses of taxol to be used, and allows for certain patients suffering severe myelosuppression to be continued on taxol treatment whereas, in the past, such patients may not have been allowed to continue on taxol.

#### HYPERSENSITIVITY REACTIONS

35% (57/157) of the patients exhibited some type of hypersensitivity reaction. Only two hypersensitivity reactions (2 of 157 patients or 1%) were reported which required acute therapeutic intervention.

Table 4 below lists the number and percentage of patients demonstrating hypersensitivity reactions per treatment Arm and also provides the type of HSR per course.

Table 4  
Hypersensitivity Reactions (HSR) Per Treatment Arm

	175/24 n (%)	175/3 n (%)	135/24 n (%)	135/3 n (%)	TOTAL n (%)
per patient					
Number of patients analyzed	45	29	44	39	157
- Patients reporting a HSR	6 (36)	12 (41)	18 (41)	11 (28)	57 (36)
Per Course					
Number of courses analyzed	163	92	141	132	528
- Courses with a reported HSR	46 (28)	23 (25)	44 (31)	23 (17)	136 (26)
Type of HSR per course <sup>(1)</sup>					
- Flushing	32	16	40	15	103
- Rash	3	6	6	6	21
- Hypotension	10	1	1	1	13
- Dyspnea	-	-	3	2	5
- Edema face	1	1	-	-	2
- Eye disorder	-	-	-	2	2
- Pruritis	-	-	-	2	2
- Headache	-	-	1	-	1
- Arrhythmia	1	-	-	-	1
- Hypertension	1	-	1	-	1
- Tachychardia	-	-	1	-	1
- Nausea/ Vomiting	-	-	1	-	1
- Chest pain	-	-	-	-	-

(1) More than 1 sign and symptom may be experienced in each course.

The most frequent symptoms were flushing, mainly confined to the face, following by skin rash, hypotension, and dyspnea.

Of the two patients suffering severe hypersensitivity reactions, one patient was not rechallenged with taxol. The other patient suffering a severe hypersensitivity reaction received a 135 mg/m<sup>2</sup> 24-hour infusion first course of taxol without experiencing a severe hypersensitivity reaction. Due to WHO Grade IV neutropenia for more than 7 days, the scheduled dose for course 2 was reduced by 20%. During the second course, the delivery of less than 1 ml of taxol infu-

sion induced tachychardia and shortness of breath, requiring the infusion to be stopped. The patient developed an extreme general flush, with a heart rate of 150 per minute (regular) and the blood pressure was 150/100. The allergic reaction resolved completely after the administration of 50 mg benadryl IV and 35 mg adrenalin s.c. The infusion of taxol was restarted after an interruption of 70 minutes at the regular infusion rate without further problems.

Another patient encountered a hypersensitivity reaction, which prompted the investigator to interrupt the infusion. However, this incident did not qualify as a significant HSR. During a first course, the patient received 135 mg/m<sup>2</sup> during a 24-hour infusion. Course 1 was administered uneventfully. Taxol infusion during course 2 was interrupted after 1 minute (less than 1 mg of taxol) due to dyspnea, flushing, and nausea, which was treated with 5 mg of chlorphenamine. The patient received another 250 mg hydrocortisone, and the taxol infusion was recommenced 70 minutes after. The total infusion time was 28 hours, 15 minutes with no further occurrence of hypersensitivity reaction. Course 3 was administered uneventfully with normal premedication.

Further examples of adverse reactions are discussed later.

#### PERIPHERAL NEUROPATHY

80 of 157 patients (51%) experienced some sign or symptom of peripheral neurotoxicity. The incidents in the high dose arms was 66% (49/74), while the incidents in the low dose arms was 37% (31/83). the incidents of peripheral neuropathy in the long-term (24-hour) infusion was 48% (43/89), while the incidents of peripheral neuropathy in the short-term infusion arms was 54% (37/68).

Prior to taxol treatment, 75% (118/157) of patients were asymptomatic ; of these, 44 patients (37%) developed some peripheral neuropathy symptoms. Overall, 54 of 157 patients (34%) developed, or had worse peripheral neuropathy symptoms, as can be seen by Table 5 below.

The substantial reduction in peripheral neurotoxicity symptoms (PNS) in patients receiving lower dosages of taxol allows for more flexibility in treating patients, since lower taxol dosages over longer infusion periods can be used for patients suffering from PNS while higher doses and/or shorter infusion periods can be used for patients not suffering from PNS.

TABLE 5  
Peripheral Neuropathy Symptoms (PNS) and Taxol Dosing By Treatment Arm

	175/24 n=45	175/3 n=29	135/24 n=44	135/3 n=39	TOTAL n=157
	n (%)	n (%)	n (%)	n (%)	n (%)
Number of patients who developed or worsened PNS	20 (44)	18 (62)	7 (16)	8 (21)	54 (34)
First occurrence/worsening of PNS					
- by courses					
- course 1	9	7	3	4	23/157 (15)
- course 2	8	9	2	-	19/143 (13)
- course 3	1	1	1	1	4/95 (4)
- course 4 and more	2	1	1	3	7/69 (10)
- by cumulative dose of taxol					
- ≤ 200 mg/m <sup>2</sup>	9	7	3	4	23
- 201-400 mg/m <sup>2</sup>	8	9	3	1	22
- 401-600 mg/m <sup>2</sup>	2	1	1	2	4
- > 600 mg/m <sup>2</sup>	1	1	1	2	5

It is clear that peripheral neuropathy symptoms (PNS) are reduced when a dosage of about 135 mg/m<sup>2</sup> taxol is provided rather than a dosage of about 175 mg/m<sup>2</sup>.

Further examples of adverse drug reactions, and the procedures used to continue treatment follow.

Patient BB-2 was allocated to the 135 mg/m<sup>2</sup>, 3 hour arm. Shortly after beginning her second cycle of treatment, she developed asymptomatic bradyarrhythmia characterized by short periods of AV block or sinus pauses accompanied by some ventricular extrasystoles. She had some extrasystoles in cycle 1 as well. There was no prior cardiac history and subsequent investigations were normal. She had a pacemaker inserted and was retreated with a third cycle. The bradyarrhythmia appeared to have a definite relation to taxol, and the patient recovered with treatment.

Patient BB-3 was allocated to the 175 mg/m<sup>2</sup>, 3 hour arm. Shortly after beginning cycle 2, she developed a hypersensitivity reaction, characterized by generalized urticaria, diaphoresis, and dyspnea. The infusion was interrupted and

she recovered quickly after treatment with epinephrine and antihistamine. She was retreated using the re-challenge amendment discussed above. The HSR appeared to be definitely related to taxol, and the patient recovered with treatment.

Patient DF-1 was randomized to the 135 mg/m<sup>2</sup>, 24 hour arm. During her first treatment, she had 2 episodes of asymptomatic bradycardia, during which the infusion was interrupted for durations lasting 3 and 5 minutes, respectively. She also developed a mild skin rash. However, the infusion was completed. The bradycardia appeared related to taxol, and the patient recovered.

Patient IM-7 was allocated to the 135 mg/m<sup>2</sup>, 24 hour infusion, and experienced a non-significant HSR during cycle 2. Her first cycle of treatment had been uneventful ; however, 5 minutes after the 2nd treatment began, she became flushed and dyspneic, with nausea (no vomiting). The infusion was stopped, 5 mg chlorpheniramine was given and symptoms rapidly resolved. The patient was re-treated according to the retreatment protocol discussed earlier with no problem, aside from minor facial rash. The HSR appeared to be related to taxol.

Patient MP-7 was allocated to the 135 mg/m<sup>2</sup>, 24 hour infusion. About 30 minutes after cycle 1 began, she became hot, flushed, and slightly dyspneic (BP 114/80, pulse 112). Taxol was stopped, she was given diphenhydramine, and the reaction resolved immediately. The patient was re-treated according to the re-treatment protocol without event. Thus, the HSR appears related to taxol.

Patient VA-30 was randomized to the 135 mg/m<sup>2</sup>, 24 hour arm. During her second treatment, she developed flushing and a sense of tightness in her throat. The infusion was stopped for a short while, and repeat doses of steroid, antihistamine and ranitidine were given. Taxol was restarted with no further problems ; this indicates that the HSR was caused by taxol.

The success of the use of the new taxol products and infusion protocol of the present invention in the treatment of ovarian cancer makes it readily apparent that anti-neoplastically effective dosages of taxol can be infused over much shorter time periods than was previously believed possible, without inducing severe hypersensitivity reactions or inducing fatal anaphylactic shock. Thus, it is contemplated that the infusion protocol of the new products of the present invention may be utilized to treat solid tumors and leukemias, such as but not limited to lung cancer, breast cancers, and ovarian cancers. It is to be understood that treatment of different forms of cancer may require the adjustment of the taxol dosage to have optimal efficacy.

The foregoing clearly establishes that taxol is both safe and effective in the treatment of cancer, such as ovarian cancer, when administered with the products and according to the protocol of the present invention. In particular, by use of a 3-hour infusion of about 135 mg/m<sup>2</sup> taxol, following premedication, a substantial reduction results in the frequency of myelotoxicity and neuropathy associated with the administration of taxol to patients suffering from cancer. Further, patients who exhibits severe hypersensitivity reactions can be rechallenged with taxol after treating the HSR symptoms by use of an infusion of about 24 hours or greater, preferably using a dosage of about 135 mg/m<sup>2</sup> to about 175 mg/m<sup>2</sup>. Preferably, colony stimulating factors are administered to assist in ameliorating myelosuppression.

The use of lower dosages of taxol to achieve antineoplastic results will allow for more patients to be treated with the present limited supply of taxol. Further, depending upon the toxicities noted in a patient during treatment with taxol according to the present products and protocol, the duration of infusion can be extended or shortened, or the taxol dosage can be reduced or increased, thus providing more flexibility in treating cancer with taxol. Further, patients capable of handling higher doses of taxol can be administered up to about 275 mg/m<sup>2</sup> ; should the patient encounter severe toxicity, such as a severe neuropathy, the products and protocol of the present invention allows for reducing the dosage.

#### Claims

1. Use of taxol and sufficient medications to prevent severe anaphylactic reactions, for manufacturing a medicamentation for simultaneous, separate, or sequential application for the administration of from 135 mg/m<sup>2</sup> up to 175 mg/m<sup>2</sup> taxol over a period of about 3 hours or less as a means for treating cancer and simultaneously reducing neutropenia.
2. Use according to claim 1, characterized in that the amount of taxol is 135 mg/m<sup>2</sup>.
3. Use according to anyone of the preceding claims for simultaneous, separate, or sequential use in the therapy of solid tumors or leukemia.
4. Use according to anyone of the preceding claims, characterized in that said medications include at least a compound selected from the group consisting of steroids, antihistamines and H<sub>2</sub> receptor antagonists.
5. Use according to anyone of the preceding claims, characterized in that said medications are selected from the group consisting of Ranitidine, Dexamethasone, Diphenhydramine, Famotidine, Hydrocortisone, Clemastine, Cimetidine, Prednisone, Chlorpheniramine, Chlorphenamine, Dimethindene maleate, and Promethazine.



6. Use according to anyone of the preceding claims, characterized in that the said medicamentation further comprises an effective amount of a colony stimulating factor.
7. Use according to claim 1 in ovarian cancer therapy.
8. Use according to claim 7, characterized in that said medications comprise at least a compound selected from the group consisting of steroids, antihistamines, H<sub>2</sub> receptor antagonists, in a sufficient amount to prevent fatal anaphylactic reactions.
9. Use according to claim 8, characterized in that the said medicamentation further comprises an effective amount of a colony stimulating factor sufficient to at least reduce myelotoxicity.

#### Patentansprüche

1. Verwendung von Taxol und medizinischen Zusätzen in ausreichender Menge, um ernsthaften anaphylaktischen Reaktionen vorzubeugen, zur Herstellung eines Arzneimittels zur gleichzeitigen, getrennten oder aufeinanderfolgenden Anwendung für die Verabreichung von 135 mg/m<sup>2</sup> bis zu 175 mg/m<sup>2</sup> Taxol über einen Zeitraum von etwa 3 Stunden oder weniger als ein Mittel zur Behandlung von Krebs und zur gleichzeitigen Reduzierung von Neutropenie.
2. Verwendung nach Anspruch 1, dadurch gekennzeichnet, daß die Menge an Taxol 135 mg/m<sup>2</sup> beträgt.
3. Verwendung nach einem der vorstehenden Ansprüche zur gleichzeitigen, getrennten oder aufeinanderfolgenden Verwendung in der Therapie von malignen Tumoren oder Leukämie.
4. Verwendung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, daß die Beimischungen wenigstens eine Verbindung, gewählt aus Steroiden, Antihistaminen und H<sub>2</sub>-Rezeptorantagonisten, beinhalten.
5. Verwendung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, daß die Beimischungen gewählt sind aus Ranitidin, Dexamethason, Diphenhydramin, Famotidin, Hydrocortison, Clemastin, Cimetidin, Prednison, Chlorpheniramin, Chlorphenamin, Dimethindenmaleat und Promethazin.
6. Verwendung nach einem der vorstehenden Ansprüche, dadurch gekennzeichnet, daß das Arzneimittel weiterhin eine wirksame Menge eines Kolonie-stimulierenden Faktors umfaßt.
7. Verwendung nach Anspruch 1 in der Eierstockkrebstherapie.
8. Verwendung nach Anspruch 7, dadurch gekennzeichnet, daß die Beimischungen wenigstens eine Verbindung, gewählt aus Steroiden, Antihistaminen und H<sub>2</sub>-Rezeptorantagonisten umfassen, in einer hinreichenden Menge, um lebensbedrohlichen anaphylaktischen Reaktionen vorzubeugen.
9. Verwendung nach Anspruch 8, dadurch gekennzeichnet, daß das Arzneimittel weiterhin eine wirksame Menge eines Kolonie-stimulierenden Faktors umfaßt, die ausreicht, um die Myelotoxizität wenigstens zu mindern.

#### Revendications

1. Utilisation de taxol et de médicaments suffisantes pour prévenir des réactions anaphylactiques graves, pour la fabrication d'une médication pour une application simultanée, séparée ou séquentielle pour l'administration de 135 mg/m<sup>2</sup> jusqu'à 175 mg/m<sup>2</sup> de taxol sur une période d'environ 3 heures ou moins en tant que moyen pour traiter le cancer et réduire simultanément la neutropénie.
2. Utilisation selon la revendication 1, caractérisée en ce que la quantité de taxol est de 135 mg/m<sup>2</sup>.
3. Utilisation selon l'une quelconque des revendications précédentes pour utilisation simultanée, séparée ou séquentielle dans la thérapie des tumeurs solides ou de la leucémie.
4. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que lesdites médicaments incluent au moins un composé choisi dans le groupe consistant en les stéroïdes, les antihistamines et les antagonistes de récepteur H<sub>2</sub>.

5. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que lesdites médicaments sont choisies dans le groupe consistant en la Ranitidine, la Dexaméthasone, la Diphénhydramine, la Famotidine, l'Hydrocortisone, la Clémastine, la Cimetidine, le Prednisone, le Chlorphéniramine, la Chlorphénamine, le Diméthindène maléate et la Prométhazine.

5

6. Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que ladite médication comprend de plus une quantité efficace d'un facteur de stimulation des colonies.

7. Utilisation selon la revendication 1 dans la thérapie du cancer des ovaires.

10

8. Utilisation selon la revendication 7, caractérisée en ce que lesdites médicaments comprennent au moins un composé choisi dans le groupe consistant en les stéroïdes, les antihistamines, les antagonistes de récepteur H<sub>2</sub>, en une quantité suffisante pour prévenir des réactions anaphylactiques fatales.

15

9. Utilisation selon la revendication 8, caractérisée en ce que ladite médication comprend de plus une quantité efficace d'un facteur de stimulation des colonies suffisante pour au moins réduire la myélotoxicité.

20

25

30

35

40

45

50

55